Navigation Links
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
Date:1/18/2012

uct portfolio centered on mature, high selling products to a more diverse portfolio focused on new products. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.

Takeda also plans to consolidate its R&D sites to ensure ongoing support for all marketed products and support development and global registration of new products throughout the combined footprint. Takeda will invest strongly in R&D focused on core therapeutic areas, while effectively deploying both internal and external resources to create innovative drugs and transform treatment paradigms. The integrated R&D organization aims to support Takeda's global vision of bringing innovative products to address patients' needs by maximizing efficiency, driving standardization, optimizing resource utilization and driving productivity.  

To meet its goals, Takeda plans the consolidation of a number of sites and functions, including the potential merger or liquidation of subsidiaries mainly in Europe, and a reduction of workforce in the United States, primarily within Takeda Pharmaceuticals North America. The necessary cost for this plan is estimated approximately Yen 70 billion in total during fiscal 2011 - 2015. During this period, Takeda will achieve cost synergies of approximately Yen 200 billion. The cost synergy in Europe estimated in fiscal 2014 is now Yen 40 billion which is 10 billion greater than the original forecast announced in May 2011. Takeda plans a reduction of the Takeda global workforce by approximately 2,800 (2,100 mainly in Europe and 700 in the U.S.) positions by the end of fiscal 2015 across the functions of R&D, commercial, operations and G&A.

Employees affected by the measures will be offered appropriate guidance and support in accordance with Takeda's corpora
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin
2. U.S. Food and Drug Administration (FDA) Delays Review of Takedas Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone
3. Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
4. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
5. Takeda Completes Acquisition and Names New CEO of Nycomed
6. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
7. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
8. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
9. Takeda to Acquire Nycomed
10. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
11. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... N.Y. and HAMBURG, Germany , Aug. 21, 2014 ... is collaborating with Deutsches Elektronen-Synchrotron ( DESY ), a ... , to speed up management and storage of massive ... and Analytics architecture based on IBM software defined ... of data at peak performance and help scientists worldwide ...
(Date:8/21/2014)... 2014 BreedIT Corp., (OTCQB: ... exclusive worldwide license holder and distributor of highly ... researchers, today is pleased to announce the formation ... Ltd, a leading Israeli medical Cannabis breeder. ... new breeds of medical Cannabis to meet the ...
(Date:8/21/2014)... N.J. , Aug. 21, 2014  Armada ... group purchasing organization (GPO), is pleased to announce ... collaborate on a host of innovative specialty pharmacy ... Aurora deliver enhanced therapy management services to specialty ... (OTM) system. Aurora will use the ...
Breaking Medicine Technology:DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3
... 5 Salmonella bacteria is normally very toxic ... to prevent it from causing illness and instead kill cancer ... – a medical oddity first observed in the 1890s, but ... non toxic Salmonella variations. Genetically-modified ...
... 5 Generex Biotechnology Corporation (Nasdaq: GNBT ... in a letter to shareholders from Interim President and ... for growth. The letter to shareholders reads as follows: ... at Generex, the management team has been working diligently ...
Cached Medicine Technology:Botanic Oil Innovations Funds Human Clinical Study Using Non-Toxic Salmonella as Cancer Medicine 2Generex Biotechnology Provides a Corporate Update to Address Management's Strategic Initiatives for Growth 2Generex Biotechnology Provides a Corporate Update to Address Management's Strategic Initiatives for Growth 3Generex Biotechnology Provides a Corporate Update to Address Management's Strategic Initiatives for Growth 4Generex Biotechnology Provides a Corporate Update to Address Management's Strategic Initiatives for Growth 5Generex Biotechnology Provides a Corporate Update to Address Management's Strategic Initiatives for Growth 6Generex Biotechnology Provides a Corporate Update to Address Management's Strategic Initiatives for Growth 7Generex Biotechnology Provides a Corporate Update to Address Management's Strategic Initiatives for Growth 8
(Date:8/22/2014)... Washington, DC (PRWEB) August 22, 2014 ... a little easier in the coming year for four ... from the National League for Nursing Foundation for ... candidates – will share $28,000, $10,000 more than in ... Margaret Ann Kerr Endowment and Elizabeth Isaac Marcil Endowment ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... by Dr. Sen and Dr. Samantha Pearson to help ... contacts, and avoid corrective vision surgery by instead improving ... Michaels, prompting an investigative review. , “There’s a ... of dollars in revenue each year—it’s because people just ...
(Date:8/22/2014)... August 22, 2014 Advancements in ... some clinical applications due to their cost-effectiveness, non-invasiveness, ... innovations in ultrasound, such as the evolution of ... to keep the market moving throughout 2014 and ... can enhance not only the point-of-care (POC) testing ...
(Date:8/22/2014)... New York, New York (PRWEB) August 22, 2014 ... ) continue to be filed in U.S. courts ... cardiovascular events due to their use of prescription ... to court documents, a new claim was filed ... California man who allegedly suffered life-threatening heart issues ...
(Date:8/22/2014)... Eagerly embracing intended parents around the ... now offers the top male infertility programs — run ... fertility network of IVFinMexico.com continues to shape ... care, female and male infertility, advanced research and education. ... so eminently set by company CEO and Founder Tolga ...
Breaking Medicine News(10 mins):Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 2Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 4
... the development of vascular diseases may also contribute to ... access in dialysis patients, according to a study appearing ... the American Society of Nephrology (JASN). "Our ... may contribute to the relatively poor outcomes regarding the ...
... HealthDay Reporter , WEDNESDAY, Dec. 22 (HealthDay News) -- ... as the "stroke belt" eat twice as much fried fish ... according to a new study looking at regional and ethnic ... The stroke belt, with more deaths from stroke than ...
... , WEDNESDAY, Dec. 22 (HealthDay News) -- A gene ... patients with glioblastoma brain cancer has been identified by ... as NFKBIA -- contributes to tumor development, promotes resistance ... of patients with glioblastoma, the most common and deadly ...
... , WEDNESDAY, Dec. 22 (HealthDay News) -- ... the hospital increases the risk of complications from infections ... new study. U.S. researchers looked at patients who ... surgery: 87,318 coronary artery bypass graft (CABG) procedures; 46,728 ...
... sex are you? Sex in mammals is genetically ... have one X and one Y chromosome. However, some individuals ... a condition known as XX male sex reversal. A team ... has now determined that overexpression of the Sox3 gene in ...
... On December 14-15, 2010, the U.S. Food and Drug Administration ... that may affect the regulation of dental amalgam. At the ... the FDA conduct further review of the material,s safety. ... Final Rule ( http://bit.ly/FDA2009FinalRule ) from the FDA that reclassified ...
Cached Medicine News:Health News:Why does dialysis fail? 2Health News:Too Much Fried Fish Might Help Make South the 'Stroke Belt' 2Health News:Too Much Fried Fish Might Help Make South the 'Stroke Belt' 3Health News:Gene Mutation Found in One of Four Cases of Deadly Brain Cancers 2Health News:Timely Surgery Appears to Cut Infection Risk, Costs 2Health News:JCI table of contents: Dec. 22, 2010 2Health News:JCI table of contents: Dec. 22, 2010 3Health News:JCI table of contents: Dec. 22, 2010 4Health News:JCI table of contents: Dec. 22, 2010 5Health News:JCI table of contents: Dec. 22, 2010 6Health News:JCI table of contents: Dec. 22, 2010 7Health News:JCI table of contents: Dec. 22, 2010 8Health News:JCI table of contents: Dec. 22, 2010 9Health News:JCI table of contents: Dec. 22, 2010 10Health News:JCI table of contents: Dec. 22, 2010 11Health News:JCI table of contents: Dec. 22, 2010 12Health News:AADR testifies to the FDA advisory panel on dental amalgam 2
300 L, Bulk Recommended for 250 and 300 L pipettes....
... PerkinElmer manufactures Robotic Certified Tips for ... dispensing systems. Manufactured with the highest quality, ... to provide unparalleled accuracy in high throughput ... with a volume range from 0.5 L ...
MBP's 200 ul large orifice tip is perfect for handling fragile cells, viscous samples, and genomic DNA....
This extra long 180 ul pipet tip will reach the bottom of large tubes and vials, preventing your pipettor from contacting the sample container....
Medicine Products: